Form PTO-1449 U.S. Department of Commerce (REV. 8-83) Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT		Atty. Docket: In re Application No. 10/826,859 (Myers 1747-00) Applicant: Myers et al.			
(Use several sheets) necessary)			Filing Date: Group: 1614 April 16, 2004		
U.S. PATENT	DOCUMENTS				
Examiner's Initials	U.S. Patent No.	Applicant	Issue Date	Class	Subclass
RR	*6,569,859	Corey	May 27, 2003	514	250
RR	*6,348,467	Corey	February 19, 2002	514	250
RR	*6,316,214	Rinchart et al.	November 13, 2001	435	25
RR	6,258,539	Hunkapiller et al.	July 10, 2001	435	6
RR	*6,124,293	Rinchart et al.	September 26, 2000	514	250
RR	*6,124,292	Corey	September 26, 2000	514	250
RR	5,939,273	Lussow et al.	August 17, 1999	435	7.1
RR	5,786,461	Buchardt et al.	July 28, 1998	536	18.7
RR	*5,834,228	Becker et al.	November 10, 1998	435	23
RR	5,773,571	Nielsen et al.	June 30, 1998	530	300
RR	*5,721,362	Corey et al.	February 24, 1998	540	466
RR	5,652,355	Metelev et al.	July 29, 1997	536	24.5
RI?	5,646,260	Letsinger et al.	July 8, 1997	536	23.1
RR	5,580,969	Hoke et al.	December 3, 1996	536	24.5 .
1515	5,539,082	Nielsen et al.	July 23, 1996	530	300
RR	5,476,925	Letsinger et al.	December 19, 1995	536	23.1
RR	5,278,302	Caruthers et al.	January 11, 1994	536	24.5
RR	5,153,319	Caruthers et al.	October 6, 1992	536	27
RIR	*5,023,184	Reichenbach et al.	June 11, 1991	435	252.1
RR	4,973,679	Caruthers et al.	November 27, 1990	536	27 .
RR	*4,837,149	Arai et al.	June 6, 1989	435	119
RR	4,668,777	Caruthers et al.	May 26, 1987	536	27
RR	4,500,707	Caruthers et al.	February 19, 1985	536	27
RR	4,458,066	Caruthers et al.	July 3, 1984	536	27
RR	4,419,732	Lambregts et al.	December 6, 1983	364	428
124	*4,372,947	Arai et al.	February 8, 1983	424	121
RR	*4,248,863	Arai	February 3, 1981	424	121

2-17-05

U.S. PATENT	APPLICATIONS					
Examiner's Initials:	Publication Number:	Applicant:	Publication Date:	Group :	Art Unit:	
RR	US2003/0083495	Corey	May 1, 2003			
FOREIGN PA	FOREIGN PATENT DOCUMENTS					
Examiner's	Document No.	Country	Date	Translatio	on	
Initials				Yes	No	
rer?	*DE 28 39 668	Germany	3/1979			
RR	*EP 0 329 606	Europe	03 February 1989			
RR	*EP 0 233841	Europe	12 December 1987			
RR	*EP 0 173 649	Europe	26 August 1985			
> 1515	*ЈР 63-2991	Japan	07 January 1988			
RR	*ЛР 61-58593	Japan	25 March 1986	:		
ar_	*JP 57-50896	Japan	25 March 1982			
RR	*ЈР 56-135486	Japan .	22 October 1981		<u> </u>	
KK	*WO 01/87895	International	22 November 2001			
RR	*WO 01/87894	International	22 November 2001			
RR	*WO 01/53299	International	26 July 2001			
15/5	*WO 01/19824	International	22 March 2001			
RR	*WO 00/69862	International	23 November 2000			
1515	*WO 00/18233	International	06 April 2000			
RP.	*WO 98/12198	International	26 March 1998		,	
OTHER DOCU	MENTS		"			
Examiner's Initials	Citation (Including	Author, Title, Date, Pert	inent Pages, Etc.)			
RN	*Arai, et al., "Increased Production of Saframycin A and Isolation of Saframycin S", The Journal of Antibiotics, XXXIII(9): 951-960, 1980.					
MS	*Arai, Directed Biosynthesis of New Saframycin Derivatives with Resting Cells of Streptomyces Lavendulae", Antimicrobial Agents and Chemotherapy, 28(1): 5-11, 1985.					
, RR	Arai, T., "Isoquinolinequinones from Actinomycetes and Sponges", The Alkaloids, XXI: 56-100, 1983.					
ompre cité	Arai, et al, "Biological Activity of Saframycins with Special Reference to Action Mechanism", pg. 89-95.					
RR	1027, 1980.					
RN	Arai, et al., "Some Chemotherapeutic Properties of Two New Antitumor Antibiotics, Saframycins A and C", Gann, 71: 790-796, 1980.					
<u> </u>		Arai, et al., In Advances in Cancer Chemotherapy; University Park Press, Baltimore, 235-251, 1978.				
LUS	1018, 1977.	Arai, et al., "New Antibiotics Saframycins A, B, C, D and E", <i>The Journal of Antibiotics</i> , 30: 1015-1018, 1977.				
RP	*Bodian, et al., "Inhibition of the Fusion-Inducing Conformational Change of Influenza Hemagglutinin by Benzoquinones and Hydroquinones", <i>Biochemistry</i> , 32: 2967-2978, 1993.					
RP		*Davidson, B., "Renieramycin G, A New Alkaloid from the Sponge Xestospongia Caycedoi", Tetrahedron Letters, 33(26): 3721-3724, 1992.				

R Kaymond 2-17-05 2 of 6

RR RR RR RR	*Ekambareswara, et al., "DNA Sequence Selectivities in the Covalent Bonding of Antibiotic Saframycins Mx1, Mx3, A, and S Deduced from MPE-Fe(II) Footprinting and Exonuclease III Stop Assays", Biochemistry, 31: 12076-12082, 1992. *Ekambareswara, et al., "Mode of Action of Saframycin Antitumor Antibiotics: Sequence Selectivities in the Covalent Binding of Saframycins A and S to Deoxyribonucleic Acid", Chem. Res. Toxicol. 3:262-267, 1990. *Evans, et al., "Stereoselective Synthesis of (±)-Cyanocycline", J. Am. Chem. Soc. 108: 2478-2479, 1986. *Flanagan, et al., "Synthetic Studies on Quinocarcin: Total Synthesis of (±)-Quinocarcinamide Via Dipole Cycloaddition of an Azomethine Ylide Generated by NBS Oxidation", J. Org. Chem. 60: 6791-6797, 1995. *Fukuyama, et al., "Total Synthesis of (±)-Saframycin A", J. Am. Chem. Soc. 112: 3712-3713, 1990.	
RR RR	in the Covalent Binding of Saframycins A and S to Deoxyribonucleic Acid", Chem. Res. Toxicol. 3:262-267, 1990. *Evans, et al., "Stereoselective Synthesis of (±)-Cyanocycline", J. Am. Chem. Soc. 108: 2478-2479, 1986. *Flanagan, et al., "Synthetic Studies on Quinocarcin: Total Synthesis of (±)-Quinocarcinamide Via Dipole Cycloaddition of an Azomethine Ylide Generated by NBS Oxidation", J. Org. Chem. 60: 6791, 1995.	
RR	 *Flanagan, et al., "Synthetic Studies on Quinocarcin: Total Synthesis of (±)-Quinocarcinamide Via Dipole Cycloaddition of an Azomethine Ylide Generated by NBS Oxidation", J. Org. Chem. 60: 6791-6797, 1995. 	
	Dipole Cycloaddition of an Azomethine Ylide Generated by NBS Oxidation", J. Org. Chem. 60: 6791-6797, 1995.	
RR	*Fukuyama, et al., "Total Synthesis of (±)-Saframycin A", J. Am. Chem. Soc. 112: 3712-3713, 1990.	
विर	*Fukuyama, et al., "Stereocontrolled Total Sunthesis of (±)-Saframycin B", J. Am. Chem. Soc., 104: 4957-4958, 1982.	
RR	*Fukuyama, et al., A Stereocontrolled Total Synthesis of (±)-Renieramycin A", Tetrahedron Letters, 31(42): 5989-5992, 1990.	
RR	*Ha, et al., X-Ray Structures of H5 Avian and H9 Swine Influenza Virus Hemagglutinins Bound to Avian and Human Receptor Analogs", <i>PNAS</i> , 98(20): 11181-11186, 2001.	
RR	Hill, et al., "Computer Simulation of the Binding of Saframycin A to d(GATGCATC)", J. Med. Chem. 34: 1990-1998, 1991.	
rr	*Hoffman, et al., "Structure-Based Identification of an Inducer of the Low-pH Conformational Change in the Influenza Virus Hemagglutinin: Irreversible Inhibition of Infectivity", <i>Journal of Virology</i> , 71(11): 8808-8820, 1997.	
RR	*Ishiguro, et al., "Binding of Saframycin A, a Heterocyclic Quinone Anti-Tumor Antibiotic to DNA as Revealed by the Use of the Antibiotic Labeled with [14C]Tyrosine or [14C]Cyanide", <i>The Journal of Biological Chemistry</i> , 256(5): 2162-2167, 1981.	
RA	*Ishiguro, et al., "Mode of Action of Saframycin A, A Novel Heterocyclic Quinone Antibiotic. Inhibition of RNA Synthesis in Vivo and In Vitro", <i>Biochemistry</i> , 17(13): 2545-2550, 1978.	
RR	Jimeno, et al., "Progress in the Acquisition of New Marine-Derived Anticancer Compounds: Development of Ecteinascidin-743 (ET-743), Drugs Future, 21: 1155-1165, 1996.	
RR	*Kaneda, et al., "Antitumor Activity of New Semisynthetic Saframycin Derivatives", Jpn. J. Cancer Res. (Gann), 77: 1043-1049, 1986.	
RR	Kaneda, et al., "Biological Activities of Newly Prepared Saframycins", <i>The Journal of Antibiotics</i> , XL(11): 1640-1643, 1987.	
RR	*Kishi, et al., "Structure-Activity Relationships of Saframycins", The Journal of Antibiotics, XXXVII(8): 847-852, 1984.	

3 of 6

RR	*Kubu, et al., "A Synthesis of the Derivatives of 1,2,3,5,10,10a-Hexahydrobenz[f]Indolizine-6,9-Dione Having Antifungal Activity as a Simple Model of Saframycin A", Heterocycles, 42(1): 195-211, 1996.	
RR	*Kubo, et al., "Stereoselective Total Synthesis of (±)-Saframycin B", J. Org. Chem. 53: 4295-4310, 1988.	
RR	Kubo, et al., "Synthesis of Saframycins. I. Total Synthesis of (±) – Saframycin B and its Congeners", Chem. Pharm. Bull. 35(5): 2158-2161, 1987.	
RR	*Kurihara, et al., "Studies Directed Towards Total Synthesis of Saframycin: I. A Synthesis of Hexahydro-1,5-Imino-3-Benzazocin-7,10-Dione", <i>Tetrahedron Letters</i> , 23(35): 3639-3640, 1982.	
RR	*Lown, et al., "Molecular Mechanisms of Binding and Single-Strand Scission of Deoxyribonucleic Acid by the Antitumor Antibiotics Saframycins A and C", Biochemistry, 21(3): 419-428, 1982.	
RR	*Luo, et al., "Molecular Mechanism Underlying the Action of a Novel Fusion Inhibitor of Influenza A Virus", Journal of Virology, 71(5): 4062-4070, 1997.	
RK	*Martinez, et al., "Enantioselective Synthesis of Saframycin A and Evaluation of Antitumor Activity Relative to Ecteinascidin/Saframycin Hybrids", Organic Letters, 1(1): 75-77, 1999.	
RR	*Martinez, et al., "Phthalascidin, A Synthetic Antitumor Agent with Potency and Mode of Action Comparable to Ecteinascidin 743", <i>Proc. Natl. Acad Sci. USA</i> , 96: 3496-3501, 1999.	
RM	Martinez, et al., "A New, More Efficient, and Effective Process for Synthesis of a Key Pentacyclic Intermediate for Production of Ecteinascidin and Phthalascidin Antitumor Agents", <i>Organic Letters</i> , 2(7): 993-996, 2000.	
RR	*Matrosovich, et al., "The Surface Glycoproteins of H5 Influenza Viruses Isolated from Humans, Chickens, and Wild Aquatic Birds Have Distinguishable Properties", <i>Journal of Virology</i> , 73(2): 1146-1155, 1999.	
RP	*Mikami, et al., "Biosynthetic Studies on Saframycin A, A Quinone Antitumor Antibiotic Produced by Streptomyces Lavendulae", <i>The Journal of Biological Chemistry</i> , 260 (1): 344-348, 1985.	
RR	Mikami, et al., "Blue Pigmentation of Mycelia and the Synthesis of Saframycins by Streptomyces Lavendulae", Sixth Int. Symp. on Actinomyostee Biology, 297-299, 1985.	
RR	*Myers, et al., "A Concise, Stereocontrolled Snythesis of (-) - Saframycin A by the Directed Condensation of α-Amino Aldehyde Precursors", <i>Journal of the American Chemical Society</i> , 121(46): 10828-10829, 1999.	
RR	*Myers, et al., "Synthesis and Evaluation of Bishydroquinone Derivatives of (-) - Saframycin A: Identification of a Versatile Molecular Template Imparting Potent Antiproliferative Activity", J. Am. Chem. Soc. 123:5114-5115, 2001.	
RR	*Myers, et al., "Synthesis of Highly Epimerizable N-Protected α-Amino Aldehydes of High Enantiomeric Excess", <i>Tetrahedron Letters</i> , 41: 1359-1362, 2000.	
RR	*Myers, et al., "Greatly Simplified Procedures for the Synthesis of α-Amino Acids by the Direct Alkylation of Pseudoephedrine Glycinamide Hydrate", J. Org. Chem. 64: 3322-3327, 1999.	
RR	*Myers, et al., "One-Step Construction of the Pentacyclic Skeleton of Saframycin A from a "Trimer" of	

2-17-05

RR	*Myers, et al., "Preparation of Chiral, C-Protected α-Amino Aldehydes of High Optical Purity and Their Use as Condensation Components in a Linear Synthesis Strategy", J. Am Chem. Soc. 121:8401-8402, 1999.	
RP	*Myers, et al., "Synthesis of C-Protected α-Amino Aldehydes of High Enantiomeric Excess from Highly Epimerizable N-Protected α-Amino Aldehydes", Organic Letters, 2(21): 3337-3340, 2000.	
RR	*Myers, et al., "Asymmetric Synthesis of Chiral Organofluorine Compounds: Use of Nonracemic Fluoroiodoacetic Acid as a Practical Electrophile and Its Application to the Synthesis of Monofluoro Hydroxyethylene Dipeptide Isosteres within a Novel Series of HIV ProteaseInhibitors", Journal of the American Chemical Society, 123(30): 7207-7219, 2001.	
RIP	*Nobusawa, et al., "Comparison of Complete Amino Acid Sequences and Receptor-Binding Properties Among 13 Serotypes of Hemagglutinins of Influenza A Viruses", Virology, 182: 475-485, 1991.	
RR	*Parker, et al., "Approaches to the Isoquinoline Quinone Antibiotics. 1. Additions of an Amino Acid Derivative to Quinone Monoacetal", <i>Tetrahedron Letters</i> , 25(33): 3543-3546, 1984.	
RR	*Parker, et al., "Isoquinoline Quinones. Preparation of Aframycin Intermediates and a Total Synthesis of Mimosamycin", J. Org. Chem. 53:2847-2850, 1988.	
RR	Plowright, "Synthesis and Evaluation of Bishydroquinone Derivatives of (-) – Saframycin A: Identification of a Versatile Molecular Template Imparting Potent Antiproliferative Activity" J. Am. Chem. Soc. 123: 5114-5115, 2001.	
RR	*Podhorez, David., "Stepwise Approach to the 2,3-Dihydroimidazo[1,2-a]Pyridine and 5-Oxo-1,2,3,5 Tetrahydroimidazo[1,2-a] Pyridine Ring Systems", J. Heterocyclic Chem. 28: 971, 1991.	
RP	*Pospiech, et al., "Two Multifunctional Peptide Synthetases and an O-Methyltransferase are Involved in the Biosynthesis of the DNA-Binding Antibiotic and Antitumour Agent Saframycin Mx1 from Myxococcus Xanthus", <i>Microbiology</i> , 142: 741-746, 1996.	
.RR	*Pospiech, et al., "A New Myxococcus Xanthus Gene Cluster for the Biosynthesis of the Antibiotic Saframycin Mx1 Encoding a Peptide Synthetase", <i>Microbiology</i> , 141:1793-1803, 1995.	
RR	Rao, et al., "Mode of Action of Saframycin Antitumor Antibiotics: Sequence Selectivities in the Covalent Binding of Saframycins A and S to Deoxyribonucleic Acid" <i>Chem. Res. Toxicol.</i> 3: 262-267 1990.	
RR	Rao, et al., "DNA Sequence Selectivities in the Covalent Bonding of Antibiotic Saframycins Mx1, Mx3, A, and S Deduced from MPE-Fe(II) Footprinting and Exonuclease III Stop Assays", Biochemistry, 31: 12076-12082, 1992.	
RR	Reiners, W., "Saframycins, Renieramycins, and Safracins", <i>The Chemistry of Ant. Antibiotics</i> , 2: 93-119, 1988.	
RR	Rinehart, et al., "Bioactive Compounds From Aquatic and Terrestrial Sources" <i>Journal of Natural Products</i> , 53: 771-792, 1990.	
RR	*Rosenthal, et al., "Structure of the Haemagglutinin-Esterase-Fusion Glycoprotein of Influenza C Virus", <i>Nature</i> , 396:92-96, 1998.	
RP	*Saito, et al., "Synthesis of Saframycins VIII. 1. Synthesis of the ABC Ring of Safracins", Chem, Pharm. Bull. 40(10): 2620-2626, 1992.	
RR	*Saito, et al., "Synthesis of Saframycins. 3. Preparation of a Key Tricyclic Lactam Intermediate to	

RR	*Saito, et al., "Synthesis of Saframycins, VII. The Synthesis of Saframycins of Saframycins, VIII. The Synthesis of Saframycins of Saframycins, VII. The Synthesis of Saframycins of Safra	nthesis of Novel Renieramycin Congeners",	
RR	*Saito, et al., "Synthesis of Saframycins. XII. 1 Total Synthesis of (-)-N-Acetylsaframycin Mx 2 and Its epi-(+)-Enantiomer", <i>Tetrahedron</i> , 51(30): 8231-8246, 1995.		
RR	*Saito, et al., "Synthesis of Saframycins. X. 1) Transformation of (-) Saframycin A to (-)- Saframycin Mx Type Compound with the Structure Proposed for Saframycin E", Chem. Pharm. Bull. 43(5): 777-782, 1995.		
RR	*Saito, et al., "Synthesis of Saframycins. V. Selenium Oxide Oxidation of Hexahydro-1,5-Imino-3-Benzazocin-7, 10-Dione; A Useful Method for Constructing Saframycins C and D From Saframycin B", Tetrahedron, 46(23): 7711-7728, 1990.		
RR	Saito, et al., "Synthesis of Saframycins. XI. Synthetic Studies toward a Total Synthesis of Safracin A", Tetrahedron, 51(30): 8213-8230, 1995.		
KR	Saito, et al., "Synthesis of Saframycins. VI. The Useful Transformation of (-)-Saframycin A To (-)-Saframycin Mx Type Compound)", Chem. Pharm. Bull. 39(5): 1343-1345, 1991.		
KR	Sakai, et al., "Additional Antitumor Ecteinascidins from a Caribbean Tunicate: Crystal Structures and Activities in vivo" Proc. Natl. Acad. Sci. USA, 89: 11456-11460, 1992.		
RR	*Sauter, et al., "Binding of Influenza Virus Hemagglutinin to Analogs of Its Cell-Surface Receptor, Sialic Acid: Analysis by Proton Nuclear Magnetic Resonance Spectroscopy and X-Ray Crystallography", <i>Biochemistry</i> , 31: 9609-9621, 1992.		
KIR	*Staschke, et al., "Inhibition of Influenza Virus Hemagglutinin-Mediated Membrane Fusion by a Compound Related to Podocarpic Acid" <i>Virology</i> , 248:264-274, 1998.		
RR	*Shawe, et al., "Saframycin Synthetic Studies", Tetrahedron, 47(30): 5643-5666, 1991.		
RR	Taamma, et al., "Phase I and Pharmacokinetic Study of Ecteinascidin-743, A New Marine Compound, Administered as a 24-Hour Continuous Infusion in Patients with Solid Tumors", <i>Journal of Clinical Oncology</i> , 19(5): 1256-1265, 2001.		
RR	*Webster, et al., "Evolution and Ecology of Influenza A Viruses", Microbiological Reviews, 56(1): 152-179, 1992.		
RR	*Weis, et al., "Structure of the Influenza Virus Haemagglutinin Complexed with its Receptor, Sialic Acid", Nature, 333(2): 426-431, 1988.		
RR	*Winquist, et al., "Neuraminidase Inhibitors for Treatment of Influenza A and B Infections", MMWR Morbidity and Mortality Weekly Report/Recommendations and Reports, 48(RR14): 1-11, 1999.		
10P	Yazawa, et al., "Isolation and Structural Elucidation of New Saframycins Y3, Yd-1, Yd-2, Ad-1, Y2b and Y2b-d", <i>The Journal of Antibiotics</i> , XXXIX(12): 1639-1650, 1986.		
RR	*Zhou, et al., "A Novel Face Specific Mannich Closure Providing Access to the Saframycin- Ecteinascidin Series of Piperazine Based Alkaloids", <i>Tetrahedron Letters</i> , 41:2043-2046, 2000.		
PR	*Zhou, et al., "Synthetic Explorations in the Saframycin-Ecteinascidin Series: Construction of Major Chiral Subunits Through Catalytic Asymmetric Induction", <i>Tetrahedron Letters</i> , 41:2039-2042, 2000.		
1717	International Search Report issued for corresponding	PCT application PCT/US01/47399, 2001	
EXAMINER	RRushaul	DATE CONSIDERED 2-17-05	
	itial if citation considered, whether or not citation is in coconformance and not considered. Include copy of this for		

3711991